Traded Jun 11 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Loading…
Traded May 14, 2026 · Filed May 16, 2026
The CEO of United Therapeutics sold $23K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$22,748
Shares × reported transaction price
8 days after results of May 6, 2026, 83 days before results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.0% | +1.6% | +0.4% |
| 30 days | −2.7% | +0.3% | −3.0% |
| 90 days | −10.3% | +4.6% | −14.9% |
Past results only. Not a forecast.
Traded Jun 11 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
James Edgemond (CFO AND TREASURER) sold ~$25K of United Therapeutics
Scheduled in advanceJames Edgemond (CFO AND TREASURER) sold ~$84K of United Therapeutics
Scheduled in advance